Ikena Oncology, Inc. (IKNA), a targeted oncology company currently developing an EP4 antagonist (AAT-007) in the clinic originally licensed from AskAt Inc., debuted on the NASDAQ market on March 26, 2021. The company sold 7,812,500 shares at $16 each, then doubled in value over the first day of trading, closing at $32.   According to Ikena Oncology’s prospectus, it will allocate approximately $10-15 million from the offering proceeds to the development of AAT-007.